Navigation Links
IMPAKT Breast Cancer Conference: Oral presentation abstracts online
Date:5/7/2014

IMPAKT Breast Cancer Conference Media Alert: Oral presentation abstracts online

The impact of new technologies in the care of patients with breast cancer is at the core of the IMPAKT conference on translational research in breast cancer.

Check oral presentation abstracts (full text) as of Thursday, 8 May 2014 at 10:30 (CEST) http://abstracts.webges.com/impakt2014/myitinerary

Highlights

Metastatic breast cancer and development of new drugs

  • Abstract 12O - Molecular subtype of breast cancer metastases significantly influences patient post-relapse survival. N. Tobin
  • Abstract 65O - Generation of mouse models for the identification of new driver pathways of drug resistance in human breast cancer. C. Criscitiello
  • Abstract 59O - Targeting CDK4/6 in Her2 positive breast cancer: therapeutic effect, markers, and combination strategies. E. Knudsen
  • Abstract 60P - Mechanism of action for combined CDK4/6 and ER inhibition in ER positive breast cancer. M. Koehler
  • Abstract 69P - Safety and efficacy of MK-8669 (ridaforolimus) + MK-2206 (AKT inhibitor) in patients with advanced breast cancer with PI3K pathway dependence. S. Gupta

While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. In this context the Breast International Group (BIG) has just launched AURORA, which will use molecular screening to improve our understanding of metastatic breast cancer and its response or lack of response to available drug therapies. In total 1,300 women and men from about 60 hospitals in 15 European countries are expected to take part in the programme. Over time, BIG hopes to expand the programme well beyond Europe to involve several thousand more patients.

"It is almost unethical that we continue to treat women with metastatic breast cancer when we have so little knowledge of their disease. We now have powerful technologies for investigating the molecular landscape of tumours, and we have an obligation to women to establish AURORA as a large translational research effort that can hopefully lead to more effective treatments in the future." M. Piccart, Chair of BIG and Director of the Medicine Department of the Institut Jules Bordet, Brussels, Belgium

The AURORA trial will be presented during the session
Saturday, 10 May 2014, 10:45-12:35, Gold Hall

Genomics and the importance of translational research to facilitate the implementation of new discoveries into clinical practice

  • Abstract 13O - Evolutionary patterns of microRNA expression through the course of disease and therapy in recurrent breast cancer. M. Dadiani
  • Abstract 20O - Analysis of molecular scores for the prediction of distant recurrence according to body mass index and age at baseline. I. Sestak
  • Abstract 21O - A novel methylation signature that reflects intratumoral lymphocyte infiltration in breast cancer and predicts for response to anthracycline treatment. J. Jeschke

Patients with estrogen-receptor (ER) positive breast cancer receive hormonal treatments after surgery, but sometimes chemotherapy is also needed. The Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey investigated on the criteria used to decide about chemotherapy in this patient population. Results show that criteria vary significantly across Europe.

"Data from the MAGIC survey reveal that 55% of responding physicians have adopted genomic tests in their practice but adoption varies strongly across countries. Of those physicians who have not used them, the vast majority indicate that they would like to use genomic tests in clinical practice but report lack of reimbursement, price and lack of availability as the main barriers to usage, suggesting a substantial need for broader use of genomic tests that provide information beyond traditional measures and can help physicians and patients make more informed treatment decisions." M. Aapro, MAGIC survey Lead Investigator and dean of the Multidisciplinary Oncology Institute, Genolier, Switzerland

The MAGIC survey results will be presented during the
Thursday, 8 May 2014, 17:30-19:00, Gold Foyer

Poster highlights

  • Abstract 1P Detection of breast cancer and abnormal mammograms with a rapid point-of-care breath test, M. Phillips
  • Abstract 5P The clinical impact of using the IHC4 Score: our MDT experience in a prospective series of postmenopausal women with ER positive early breast cancer, B.J. Yeo
  • Abstract 11P Optimal duration of cardiac monitoring in metastatic HER2 positive breast cancer patients receiving trastuzumab, K. Chiu
  • Abstract 17P The BRCA cancer gene as a useful predictor for double primary breast and ovarian cancer: A meta-analysis, A. Sattaratnamai
  • Abstract 70P Phase I/IIa study with CNS-targeted liposomal doxorubicin (2B3-101) in patients with brain metastases (BM) from breast cancer (BC) and other brain tumours, P.G. Aftimos

The full conference program is available at http://www.esmo.org/Conferences/IMPAKT-2014-Breast-Cancer/Programme

Around 500 attendees are expected from throughout Europe and the rest of the world.


'/>"/>

Contact: IMPAKT Press Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. International molecular screening program for metastatic breast cancer AURORA at IMPAKT
2. Eliminating the good cholesterol receptor may fight breast cancer
3. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
4. Researchers develop a new cell and animal model of inflammatory breast cancer
5. Scientists uncover multiple faces of deadly breast cancer
6. Depo-Provera Birth Control Might Raise Breast Cancer Risk
7. Routine mammograms may result in significant overdiagnosis of invasive breast cancer
8. Mayo Clinic launches whole genome breast cancer study
9. Breast cancer patients suffer treatment-related side effects long after completing care
10. Teen Drinking May Boost Odds of Precancerous Breast Changes
11. Stress contributes to cognitive declines in women with breast cancer, researcher says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: